Patents Examined by Pancham Bakshi
  • Patent number: 10844083
    Abstract: Provided herein are methods of making metal halide perovskites, including methods of making bulk crystals or micro crystals. The metal halide perovskites may be a light emitting material.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: November 24, 2020
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Biwu Ma, Chenkun Zhou, Zhao Yuan
  • Patent number: 10835500
    Abstract: A medicament for accelerated wound healing is proposed containing derivatives of the formula (I), in which R1 stands for hydrogen or methyl.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: November 17, 2020
    Assignee: Symrise AG
    Inventors: Daniela Busse, Heike Conrad, Hanns Hatt
  • Patent number: 10828625
    Abstract: The present disclosure is directed to novel crystalline germanosilicate compositions and methods of producing the same. In particular, the crystalline germanosilicate compositions are extra-large-pore compositions, designated CIT-13 possessing 10- and 14-membered rings. The disclosure describes methods of preparing these compositions using substituted benzyl-imidazolium organic structure-directing agents (OSDAs). Also disclosed are methods of using these crystalline compositions.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 10, 2020
    Assignee: California Institute of Technology
    Inventors: Joel E. Schmidt, Mark E. Davis, Ben W. Boal, Jong Hun Kang
  • Patent number: 10828390
    Abstract: The present invention relates to the technical field of reconstructive plastic surgery and cosmetology, and particularly to a biomimetic chitosan filler for preventing capsular contracture and preparation method thereof. The biomimetic chitosan filler for preventing capsular contracture includes chitosan gel, cross-linked sodium hyaluronate, surfactant, isoosmotic regulator, autologous adipose-derived stem cells, pH adjusting agent and water. The amount of the pH adjusting agent is to adjust a pH value of the chitosan filler to be within a range of 6.5-7.5. The chitosan filler prepared according to the present invention can reduce the inflammation caused by post-operative silica gel exudation, and prevent the occurrence and development of capsular contracture.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: November 10, 2020
    Assignee: SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Kun Zhang, Wanhua Chen, Bingqian Bu, Jianying Wu, Jundong Zhang, Zhen Chang, Peng Du
  • Patent number: 10829509
    Abstract: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: November 10, 2020
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Tahir Ahmed, Arie Gutman, Irina Fedotev, Igor Rukhman, Olga Grossman
  • Patent number: 10822364
    Abstract: Compositions and methods comprising metal organic frameworks (MOFs) and related uses are generally provided. In some embodiments, a MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two sets of ortho-diimine groups arranged about an organic core.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: November 3, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Mircea Dinca, Dennis Sheberla, Lei Sun, Casey R. Wade, Michael Glenn Campbell
  • Patent number: 10815267
    Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 27, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Patent number: 10808005
    Abstract: Provided are use of a compound of Formula I as a ligand of orphan nulear receptor Nur77, and in the prevention or treatment of a orphan nulear receptor Nur77 associated disease,
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: October 20, 2020
    Assignee: IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED
    Inventors: Xiaokun Zhang, Xiangzhi Lin, Ying Su, Zhiping Zeng, Mengjie Hu, Qiang Luo, Yi Zhu, Alitongbieke Gulimiran
  • Patent number: 10806708
    Abstract: In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: October 20, 2020
    Assignee: AF CHEMICALS LLC
    Inventor: Michael J Kelner
  • Patent number: 10806791
    Abstract: The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 20, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash Nair, Martin Maier
  • Patent number: 10800779
    Abstract: The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: October 13, 2020
    Assignee: Incyte Corporation
    Inventors: Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
  • Patent number: 10799502
    Abstract: Compositions for prevention or treatment of non-inflammatory neuronal damage from brain trauma and strokes are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes are also provided, and the methods include administering such compositions.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 13, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Susana Camacho, Stephanie Michlig Gonzales, Johannes Le Coutre, Henry Markram, Maurizio Pezzoli
  • Patent number: 10781175
    Abstract: Novel non-nucleoside solid supports and phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one non-nucleosidic moiety conjugated to a ligand of practical interest and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said solid supports and phosphoramidite building blocks, preferably followed by removal of protecting groups to provide oligonucleotides conjugated to ligands of interest.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 22, 2020
    Assignee: AM CHEMICALS LLC
    Inventors: Andrei Pavel Guzaev, Vladimir Y. Vvedenskiy, Khirud Gogoi
  • Patent number: 10780103
    Abstract: A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 22, 2020
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
  • Patent number: 10759820
    Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: September 1, 2020
    Assignee: Ohio University
    Inventor: Rathindra N. Bose
  • Patent number: 10760070
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: September 1, 2020
    Assignee: CureVac Real Estate GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Patent number: 10752643
    Abstract: Embodiments of the present disclosure describe compositions comprising a molecular building block (MBB) having the formula [RE6(?3-OH)8(O2C—)6N4C—)6] or [RE6(?3-OH)8(O2C—)12], wherein RE is a rare earth metal ion. Embodiments of the present disclosure further describe methods of making a metal-organic framework (MOF) composition comprising contacting one or more molecular building blocks (MBBs) with one or more bidentate ligands, wherein the MBBs have the formula [RE6(?3-OH)8(O2C—)6N4C—)6] or [RE6(?3-OH)8(O2C—)12], wherein RE is a rare earth metal ion.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 25, 2020
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Mohamed Eddaoudi, Dong-Xu Xue, Amy J. Cairns, Youssef Belmabkhout
  • Patent number: 10745343
    Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: August 18, 2020
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
  • Patent number: 10745436
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: August 18, 2020
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 10745421
    Abstract: The invention relates to a method for the cost-effective and environmentally friendly production of alkyl indium sesquichloride in high yield and with high selectivity and purity. The alkyl indium sesquichloride produced according to the invention is particularly suitable, also as a result of the high purity and yield, for the production, on demand, of indium-containing precursors in high yield and with high selectivity and purity. As a result of the high purity, the indium-containing precursors that can be produced are particularly suitable for metal organic chemical vapour deposition (MOCVD) or metal organic vapour phase epitaxy (MOVPE). The novel method according to the invention is characterised by the improved execution of the method, in particular a rapid process control. Owing to targeted and extensive use of raw materials that are cost-effective and have a low environmental impact, the method is also suitable for use on an industrial scale.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: August 18, 2020
    Assignee: UMICORE AG & CO. KG
    Inventors: Joerg Sundermeyer, Annika Frey, Wolf Schorn, Ralf Karch, Andreas Rivas-Nass, Eileen Woerner, Angelino Doppiu